Early-phase data support dose-optimized subcutaneous blinatumomab as a promising approach for relapsed or refractory B-cell acute lymphoblastic leukemias.
The post Dose-Defined Outcomes of SC Blinatumomab first appeared on Physician’s Weekly.
Early-phase data support dose-optimized subcutaneous blinatumomab as a promising approach for relapsed or refractory B-cell acute lymphoblastic leukemias.
The post Dose-Defined Outcomes of SC Blinatumomab first appeared on Physician’s Weekly.
© 2023 blackandmed
© 2023 blackandmed